Our pipeline
From a lead pancreatic cancer program to a growing platform
Saltikva® is advancing through the clinic in one of the most aggressive solid tumors, while our platform generates new constructs for a diverse set of cancers.
Saltikva® in Stage 4 metastatic pancreatic cancer
Salspera is recruiting patients in its Phase 2 study of Saltikva® in patients diagnosed with Stage 4, metastasized pancreatic cancer, with interim results already available. This lead program targets one of the highest-need cancers, where new, tolerable treatment options are urgently needed.
Saltikva® in other solid tumors
Salspera is evaluating Saltikva® in other terminal, solid tumor cancers. These programs have completed IND-enabling studies and are slated to enter the clinical stage.
New therapeutic programs
Building on the platform, Salspera has developed multiple new constructs with different capabilities — expressing various immuno-modulating proteins applicable to a diverse set of solid tumor cancers. These candidates are currently in preclinical development.
Interested in our programs?
For more detail on our clinical and preclinical programs, or on trial participation, reach out to our team.
Email info@salspera.com